Unique ID issued by UMIN | UMIN000013413 |
---|---|
Receipt number | R000015655 |
Scientific Title | BONVIVA IV drug use results surveillance |
Date of disclosure of the study information | 2014/03/17 |
Last modified on | 2019/09/19 09:17:03 |
BONVIVA IV drug use results surveillance
BONVIVA IV drug use results surveillance
BONVIVA IV drug use results surveillance
BONVIVA IV drug use results surveillance
Japan |
Osteoporosis
Medicine in general | Nephrology | Orthopedics |
Urology |
Others
NO
Confirmation of the safety and efficacy profiles of patients who are diagnosed with advanced CKD
Safety,Efficacy
Adverse reaction incidence
Observational
Not applicable |
Not applicable |
Male and Female
Patients who have no previous treatment with BONVIVA for osteoporosis and are diagnosed with osteoporosis and Grade 4 or 5 chronic kidney disease (CKD) (eGFR<30mL/min, including renal replacement therapy)
No criteria
80
1st name | Makoto |
Middle name | |
Last name | Nomura |
Chugai Pharmaceutical Co. Ltd.
Pharmacovigilance Dept.
103-8324
1-1 Nihonbashi-muromachi 2-chome, Chuo-ku Tokyo, Japan
03-3273-0769
nomuramkt@chugai-pharm.co.jp
1st name | Ayaka |
Middle name | |
Last name | Shimizu |
Chugai Pharmaceutical Co. Ltd.
Real World Data Science Dept.
103-8324
1-1 Nihonbashi-muromachi 2-chome, Chuo-ku Tokyo, Japan
03-3273-0905
shimizuayk@chugai-pharm.co.jp
Chugai Pharmaceutical Co. Ltd.
Chugai Pharmaceutical Co. Ltd.
Profit organization
None
None
None
None
NO
2014 | Year | 03 | Month | 17 | Day |
Unpublished
Completed
2014 | Year | 02 | Month | 12 | Day |
2014 | Year | 02 | Month | 12 | Day |
2014 | Year | 03 | Month | 03 | Day |
2019 | Year | 02 | Month | 28 | Day |
Adverse events
Bone mass density,bone metabolism marker and fracture
2014 | Year | 03 | Month | 13 | Day |
2019 | Year | 09 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015655